Author ORCID Identifier
https://orcid.org/0000-0002-3940-6329
https://orcid.org/0000-0002-8425-1223
https://orcid.org/0000-0001-9210-0401
https://orcid.org/0000-0002-8794-2839
N/A
N/A
N/A
N/A
Document Type
Article
Publication Date
2018
College/Unit
Statler College of Engineering and Mining Resources
Department/Program/Center
Not Listed
Abstract
As the leading cause of cancer-related mortality, lung cancer is a worldwide health issue that is overwhelmingly caused by smoking. However, a substantial minority (~25%) of patients with non–small cell lung cancer (NSCLC) has never smoked. In these patients, activating mutations of the epidermal growth factor receptor (EGFR) are more likely, which render their tumors susceptible for a finite period to treatment with EGFR tyrosine kinase inhibitors (TKIs) and confer a better prognosis than EGFR wild-type NSCLC. On progression, due to the inevitable insurgence of resistance, TKIs are generally followed by second- or third-line salvage chemotherapy until treatment failure, after which no standard treatment options are available, resulting in a poor prognosis and a high risk of death. With the focus of clinical attention on treatment with TKIs, few studies on optimal salvage therapies, including cytotoxic chemotherapy, after failure of EGFR TKIs have been reported. Despite a paucity of available data, the aim of this review is to summarize the “no-man's land” of TKI-failed EGFR-mutated NSCLC and expand on alternative strategies as well as potential future directions.
Digital Commons Citation
Oronsky, Bryan; Ma, Patrick; Reid, Tony R.; Cabrales, Pedro; Lybeck, Michelle; Oronsky, Arnold; Oronsky, Neil; and Carter, Corey A., "Navigating the “No Man's Land” of TKI-Failed EGFR-Mutated Non– Small Cell Lung Cancer (NSCLC): A Review" (2018). Faculty & Staff Scholarship. 2122.
https://researchrepository.wvu.edu/faculty_publications/2122
Source Citation
Oronsky, B., Ma, P., Reid, T. R., Cabrales, P., Lybeck, M., Oronsky, A., Oronsky, N., & Carter, C. A. (2018). Navigating the “No Man’s Land” of TKI-Failed EGFR-Mutated Non–Small Cell Lung Cancer (NSCLC): A Review. Neoplasia, 20(1), 92–98. https://doi.org/10.1016/j.neo.2017.11.001
Comments
© 2018 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1476-5586 https://doi.org/10.1016/j.neo.2017.11.001